Stockreport

Merck (MRK) Gets Exclusive Rights to Opevesostat From Partner [Yahoo! Finance]

Merck & Company, Inc. (new)  (MRK) 
Last merck & company, inc. (new) earnings: 4/28 06:45 am Check Earnings Report
US:NYSE Investor Relations: investors.merck.com/home/default.aspx
PDF rights to develop and commercialize opevesostat (previously MK-5684), an investigational CYP11A1 inhibitor for the treatment of certain patients with metastatic castrati [Read more]